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Abstract A facile and rapid access to bridgehead oxygen- and nitro-
gen-containing spiro bisheterocycles is reported. It involves a one-pot
spiro-to-spiro ring transformation of the key spiro[chromanone-hydan-
toin] compounds into new substituted spiro [hydantoin-diazole], spiro
[hydantoin-isoxazole], spiro [hydantoin-diazepine], spiro [hydantoin-
oxazepine], and spiro [hydantoin-benzodiazepine] upon reaction with
appropriate bisnucleophilic agents. The hydantoin cycle is preserved
during these chemical reactions affording the spiro bisheterocycles in
optimal yields (42–71%). This relevant spiro-to-spiro ring transforma-
tion was confirmed by NMR and single-crystal X-ray diffraction studies.
Key words spiro bisheterocycles, oxygen and nitrogen heterocycles,
bisnucleophiles, NMR, X-ray diffraction
Spiro compounds featuring bridgehead bisheterocycles
are ‘privileged structures’ because they contain a spiro link-
age and oxygen- and nitrogen-containing heterocycles that
are currently important pharmacophores developed in the
modern drug discovery.1–8 Spiro compounds belong to an
outstanding class of natural and synthetic products which
are simply defined as two-ring systems orthogonally posi-
tioned and connected by one common carbon atom adopt-
ing the sp3 tetrahedral hybridization. Looking to such a
structural feature, various chemotypes of combined spiro
bisheterocycles with significance in medicinal chemistry
are reported. For example, spiro-oxindole compounds have
gained interest, being successfully used as models for pro-
tein–protein interactions in the context of enhanced cancer
therapy.1 Spiro scaffolds are frequently found in many in-
teresting compounds exhibiting relevant biological activi-
ties and medicinal responses, such as antibiotic,3 antimalar-
ial, and cytotoxicity against cancer cell lines (KB, BC, and
NCI-H187).4 Spiro bisheterocycles are also used in pharma-
ceutical compositions for the treatment of Alzheimer’s dis-
ease, insulin resistance syndrome, and type 2 diabetes.5
Aryl-fused spiro cyclic compounds are also suitable to in-
hibit histone deacetylase, selective inducing terminal differ-
entiation, arresting cell growth, apoptosis of neoplastic
cells, and inhibiting cancer cell proliferation.7 Spiro pyrans
and spiro oxazines have found important technological ap-
plications being used as storage materials for memories and
switches due to their photochromic properties.8
Although the referred important applications of spiro
compounds, only a countable number of reports have effi-
ciently reported the design and development of synthetic
strategies of spiro bisheterocyclic scaffolds, involving multi-
component9–13 and multistep reactions.14–16 For example,
we can highlight a three-component Biginelli-like conden-
sation,9 an iodine-catalyzed four-component reaction of an
aldehyde, urea or thiourea, and cyclic 1,3-dicarbonyl com-
pounds,10 a multicomponent copper-mediated 1,3-dipolar
cycloaddition of azomethine ylides with several dipolaro-
philes,11 and of the Huisgen zwitterion with benzofuran-
2,3-diones.13
Despite of these promising results, tracking efficient
and updated methods for the construction of spiro com-
pounds remains an attractive goal, especially due to their
structural and biorelevant properties. The importance of
such compounds can be envisaged in a possible mimicking
of structural motifs found in proteins, thereby, increasing
the probability of interactions with biological systems.
In this manuscript we discuss the development of eco-
nomic synthetic routes towards a new generation of spiro
bisheterocycles. Our work started by the preparation of the
reported spiro[chromanone-hydantoin] compounds 1a,b
from chromone-2-carboxylic acid and carbodiimides using
an organocatalytic procedure.17 These key starting materi-
als were then treated with bisnucleophiles, such as methyl-
hydrazine, hydroxylamine, ethylenediamine, hydroxyeth-
yleneamine, and ortho-phenylenediamine. This synthetic
route allowed an interesting one-pot spiro-to-spiro ring
transformation of the chromanone residue of 1a,b to di-
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azole 2a,18 isoxazole 3a,19 diazepine 4a,b,20 oxazepine 5a,21
and benzodiazepine 6a,b22 maintaining the hydantoin het-
erocycle unchanged during the course of the reaction. All
these transformations are carried out under soft operating
conditions affording optimal yields (42–71% after chro-
matographic purification and recrystallization, Scheme
1).18–22 The action of bisnucleophiles, such as diamines, on
compounds 1a,b was mechanistically expected to result in a
one-step spiro-to-spiro ring transformation of the chroma-
none heterocycle through consecutive nucleophilic attacks
including the amine condensation with the carbonyl C-4
(imine formation) and chromanone ring opening over the
spiro tetrahedral carbon C-2 to give rise the new heterocy-
clic closure. Compounds 1a,b are indeed very reactive in
front of tethered nucleophiles (e.g., nitrogen and oxygen),
which may favor rearrangements or ring opening especially
via heterolytic cleavage over the highly polarized O–C σ
bond of the chromanone, rather than the N–C one of the hy-
dantoin nucleus which is found more chemically robust.17
Evidence for the mechanistic sequence was, however, found
by the isolation of the side product 7b (yield 8%) formed in
organobase media of ethylenediamine when this latter is
brought to react with 1b in order to yield the spiro product
4b (67%, Scheme 1). The reaction is probably initiated by a
deprotonation at the active methylene C-3 of 1a,b causing a
chromanone ring opening to yield the possibly isolated in-
termediate 7b (isolated only in case of the reaction between
1b and ethylenediamine).20 Such an intermediary α,β-un-
saturated ketone system 7b is found ready to undergo the
classical condensation with bisnucleophilic agents (such as
the systems of NH2–·–NH2 or NH2–·–OH) via imine forma-
tion followed by an aza- (or oxa-) Michael addition. There-
fore, the new heterocycle closure takes place giving rise to
various spiro bridgehead ring systems depending on the
spacer used in the bisnucleophilic agent (Scheme 2). Similar
reaction mechanism has been proposed in our previous
work,17 since the intermediary α,β-unsaturated ketone
structure 7 could also be isolated in low quantities under
inorganic base treatment of 1a,b using sodium ethoxide
(EtONa).
The novel synthetic procedure herein reported has sev-
eral advantages including mild synthetic conditions (with
or without catalyst) and allowed the synthesis of a wide
range of spiro asymmetric bisheterocyclic compounds. The
structural features of these spiro bisheterocycles 2–6 were
finely established based on 1D and 2D NMR studies. The
Scheme 1  Synthesis of spiro bisheterocycles 2–6. Reagents and conditions: (i) methylhydrazine, CH2Cl2, r.t.; (ii) hydroxylammonium chloride, K2CO3 
(3 equiv), THF, reflux; (iii) ethylenediamine, CH2Cl2, r.t.; (iv) hydroxyethyleneamine, CH2Cl2, r.t.; (v) o-phenylenediamine, cat. DBU, THF, reflux.
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Scheme 2  Proposed mechanism for the formation of spiro bisheterocycles 2–6
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main feature revealed in the 1H NMR spectra is the occur-
rence of geminal diastereotopic protons displaying a clear
AB spin system (2J = 14.0–17.8 Hz) with different chemical-
shift values affected by the heteroatom neighbors. In most
cases, the existence of an intramolecular hydrogen bond
between the 2′′-OH of the phenyl group and the imine ni-
trogen function is markedly visible by the appearance of a
singlet at higher frequency values ca. δ = 11 ppm. The imine
carbon is located in the 13C NMR spectra at δ = 149.5 (di-
azole, 2a), 153.8 (isoxazole, 3a), 166.7–167.0 (benzodiaze-
pine, 6a,b), 171.5 (diazepine, 4a,b), and 200.5 (oxazepine,
5a) ppm, which could be confirmed through HMBC correla-
tions entertained with the geminal diastereotopic protons
of the adjacent carbon. These protons further show import-
ant HMBC connectivities allowing the unequivocal assign-
ment of the spiro carbon (δ = 72.1–87.1 ppm), the carbonyl
C-5′ of the hydantoin cycle and the C-1′′ of the connected
phenyl group (Figure 1).
Figure 1  Main HMBC correlations of spiro bisheterocycles 2a and 4b
We note, however, that our synthetic approach toward
spiro bisheterocycles does not permit an enantioselective
isolation of enantiomerically pure compounds, as observed
from the X-ray diffraction studies performed on com-
pounds 2a, 4b, and 6b.23–25 Good-quality crystals of these
compounds were isolated from either a hexane–acetone
(5:1) or a hexane–dichloromethane (5:1) mixture by a slow
evaporation of the solvent (at 6 °C). X-ray diffraction stud-
ies confirmed the structural features unveiled from the
NMR investigations, showing the presence of three chiral
spiro asymmetric bisheterocyclic compounds (the carbon
stereocenters are depicted in Figure 2 by an asterisk). Nev-
ertheless, because of compounds crystallize in centrosym-
metric space groups (i.e., C2/c for 2a and P21/n for 4b and
6b), the unit cell contains as well the mirror image of each
molecule leading to solid-state racemic mixtures of the two
possible enantiomers for each compound. In addition, the
crystallization of the molecular units in compounds 2a and
6b is further accompanied by the inclusion of solvent mole-
cules in the interstices of the crystal structure, namely ace-
tone and dichloromethane, respectively. A common struc-
tural feature among all compounds concerns the presence
of intramolecular hydrogen bonds interconnecting the 2′′-
OH groups of the phenyl groups to the neighboring nitro-
gen of the imine C=N functional group (dashed green lines
in Figure 2).
In summary, we described the creation of a novel library
of spiro bisheterocycles via simple synthetic routes based
on the spiro-to-spiro ring transformation of the easily ac-
cessible spiro[chromanone-hydantoin] compounds into a
large diversity of nitrogen- and oxygen-containing hetero-
cycles linked to the hydantoin ring. The newly established
library of compounds would receive a great interest for fu-
ture biological screening especially in neuropathological
models due to the longstanding use of hydantoin and diaze-
pine structures in this medicinal domain.
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Figure 2  Schematic representations of the spiro asymmetric bishet-
erocyclic moieties composing the asymmetric units of the crystal struc-
tures of compounds 2a, 4b, and 6b. Nonhydrogen atoms are 
represented as thermal ellipsoids drawn at the 50% probability level and 
hydrogen atoms as small spheres with arbitrary radii. Carbon stereo-
centers are depicted by an asterisk. The solvent molecules present in 
the asymmetric units of compounds 2a and 6b (acetone and dichloro-
methane, respectively), have been omitted for clarity.
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(19) Synthesis of (R,S)-1′,3′-Dicyclohexyl-3-(2′′-hydroxyphenyl)-
spiro[4,5-dihydroisoxazole-5,4′-imidazolidine]-2′,5′-dione
(3a)
C23H29N3O4 (yellowish white solid, molecular weight 411.49
g/mol, 0.43 g, yield 42%, mp 91–92 °C). Compound 1a (1 g, 2.5
mmol) was added to K2CO3 (1 g, 7.5 mmol) in acetone (40 mL).
The reaction mixture was stirred at reflux to which hydrox-
ylammonium chloride (1 g, 14.4 mmol) was gradually added
over a period of 10 min. After 15 h, K2CO3 was filtered off, and
the solution was reduced to ca. 5 mL to which hexane (25 mL)
was added. The purified product 3a was directly recrystallized
from this hexane–acetone (5:1) solution by slow evaporation at
6 °C without any further purification steps. 1H NMR (300.13
MHz, DMSO-d6): δ = 1.00–1.99 (m, 20 H, CH2, cyclohexyl), 3.37
(tt, J = 12.1, 3.6 Hz, 1 H, H-1′′′b), 3.67 (tt, J = 12.1, 3.6 Hz, 1 H, H-
1′′′a), 3.68 and 3.71 (AB, J = 15.4 Hz, 2 H, H-4), 7.40 (ddd, J = 7.9,
5.8, 2.1 Hz, 1 H, H-5′′), 7.62–7.66 (m, 2 H, H-3′′, H-4′′), 7.87–7.91
(m, 1 H, H-6′′) ppm. 13C NMR (75.47 MHz, DMSO-d6): δ = 25.8,
26.1, 26.3, 26.4, 26.80, 26.84, 29.3, 30.2, 31.4 and 31.8 (CH2,
cyclohexyl), 31.0 (C-4), 51.3 (C-1′′′a), 53.0 (C-1′′′b), 86.1 (C-5/4′),
110.2 (C-3′′), 122.5 (C-1′′), 123.1 (C-6′′), 124.2 (C-5′′), 131.0 (C-
4′′), 153.8 (C-3), 154.5 (C-2′), 163.5 (C-2′′), 172.4 (C-5′) ppm.
HRMS (ESI+): m/z calcd for [C23H29N3O4 + Na]+: 434.2056; found:
434.2075.
(20) Synthesis of (R,S)-1′,3′-Dicyclohexyl-7-(2′′-hydroxyphenyl)-
spiro[(E)-3,4,5,6-tetrahydro-2H-1,4-diazepine-5,4′-imidazo-
lidine]-2′,5′-dione (4a) and (R,S)-1′,3′-Diisopropyl-7-(2′′-
hydroxyphenyl)-spiro[(E)-3,4,5,6-tetrahydro-2H-1,4-diaze-
pine-5,4′-imidazolidine]-2′,5′-dione (4b)
Compound 1a (1 g, 2.5 mmol) or 1b, (0.8 g, 2.5 mmol) was
added to ethylenediamine (1 mL, 15 mmol) in CH2Cl2 (20 mL).
The reaction mixture was stirred at r.t. for 4 h. After that, the
volume of CH2Cl2 was reduced to ca. 5 mL to be purified in short
plug column chromatography using CH2Cl2 as eluent. The puri-
fied products 4a or 4b were recrystallized from hexane–CH2Cl2
(5:1) solution by slow evaporation at 6 °C. In the case of com-
pound 4b synthesis, the byproduct 7b was isolated by column
chromatography and precipitated in hexane.
Compound 4a: C25H34N4O3 (pale yellow solid, molecular weight
438.56 g/mol, 0.49 g, yield 45%, mp 178–179 °C). 1H NMR
(300.13 MHz, CDCl3): δ = 1.06–2.34 (m, 20 H, CH2, cyclohexyl),
3.00–3.07 and 3.61–3.69 (2 m, 2 H, CH2, H-3), 3.25 and 3.34 (AB,
J = 14.6, 2 H, H-6), 3.24 and 3.80 (2 tt, J = 12.3, 3.8 Hz, 2 H, H-
1′′′a, H-1′′′b), 3.88 (ddd, J = 14.1, 9.1, 2.3 Hz, 1 H, H-2), 4.17 (ddd,
J = 14.1, 6.6, 1.8 Hz, 1 H, H-2), 6.73 (ddd, J = 8.2, 7.2, 1.2 Hz, 1 H,
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H-5′′), 6.93–6.98 (m, 1 H, H-3′′), 7.22 (dd, J = 8.1, 1.5 Hz, 1 H, H-
6′′), 7.27–7.31 (m, 1 H, H-4′′), 15.79 (s, 1 H, 2′′-OH) ppm. 13C
NMR (75.47 MHz, CDCl3): δ = 24.81, 24.88, 25.68, 25.71, 26.03,
26.1, 29.0, 29.4, 30.9 and 31.3 (CH2, cyclohexyl), 35.9 (C-6), 41.2
(C-3), 49.9 (C-2), 50.9 and 52.5 (C-1′′′a and C-1′′′b), 72.1 (C-5/4′),
117.1 (C-5′′), 118.93 and 118.98 (C-3′′, C-1′′), 127.2 (C-6′′), 132.8
(C-4′′), 153.3 (C-2′), 163.5 (C-2′′), 171.5 (C-7), 171.9 (C-5′) ppm.
HRMS (ESI+): m/z calcd for [C25H34N4O3 + H]+: 439.2709; found:
439.2742.
Compound 4b: C19H26N4O3 (bright yellow crystal, molecular
weight 358.43 g/mol, 0.60 g, yield 67%, mp 193–195 °C). 1H
NMR (300.13 MHz, CDCl3): δ = 1.32, 134 and 1.47 (3d, J = 6.9 Hz,
3 × 3 H, CH3, isopropyl), 1.43 (d, J = 6.8 Hz, 3 H, CH3, isopropyl),
1.86–1.97 (m, 1 H, NH), 3.00–3.07 and 3.62–3.69 (2 m, 2 H, H-
3), 3.27 and 3.32 (AB, J = 15.0 Hz, 2 H, H-6), 3.82–3.88 and 4.13–
4.19 (2 m, 2 H, H-2), 3.70–3.81 and 4.19–4.28 (2 m, 2 H, H-1′′′a,
H-1′′′b), 6.71–6.75 (m, 1 H, H-5′′), 6.95 (dd, J = 8.3, 1.1 Hz, 1 H,
H-3′′), 7.22 (dd, J = 8.1, 1.4 Hz, 1 H, H-6′′), 7.26–7.30 (m, 1 H, H-
4′′), 15.75 (s, 1 H, 2′′-OH) ppm. 13C NMR (75.47 MHz, CDCl3): δ =
19.5, 19.8, 21.2 and 21.7 (CH3, isopropyl), 36.0 (C-6), 41.5 (C-3),
43.4 and 44.5 (C-1′′′a and C-1′′′b), 50.2 (C-2), 72.2 (C-5/4′), 117.2
(C-5′′), 119.0 (C-3′′), 119.1 (C-1′′), 127.3 (C-6′′), 132.9 (C-4′′),
153.2 (C-2′), 163.5 (C-2′′), 171.5 (C-7), 172.0 (C-5′) ppm. HRMS
(ESI+): m/z calcd for [C19H26N4O3 + H]+: 359.2083; found:
359.2115.
(E,Z)-5-[2′-(2′′-Hydroxyphenyl)-2′-oxoethylidene]-1,3-diiso-
propylimidazolidine-2,4-dione (7b)
C17H20N2O4 (yellow solid, molecular weight 316.35 g/mol, 0.06
g, yield 8%, mp 144–145 °C). 1H NMR (300.13 MHz, CDCl3): δ =
1.46 and 1.49 (2d, J = 6.9 Hz, 2 × 6 H, CH3, isopropyl), 4.32–4.55
(m, 2 H, H-1′′′a, H-1′′′b), 6.82 (s, 1 H, H-1′), 6.98–6.99 (m, 1 H, H-
5′′), 7.02 (d, J = 8.4 Hz, 1 H, H-3′′), 7.47–7.57 (m, 1 H, H-4′′), 7.84
(d, J = 8.1 Hz, 1 H, H-6′′), 12.27 (s, 1 H, 2′′-OH) ppm. 13C NMR
(75.47 MHz, CDCl3): δ = 19.7 and 20.0 (CH3 isopropyl), 44.5 and
50.5 (C-1′′′a and C-1′′′b), 100.5 (C-1′), 118.6 (C-3′′), 119.2 (C-5′′),
120.8 (C-1′′), 130.8 (C-6′′), 137.0 (C-4′′), 137.2 (C-5), 153.9 (C-2),
162.9 (C-2′′), 1623.0 (C-4), 194.8 (C-2′) ppm. HRMS (ESI+): m/z
calcd for [C17H20N2O4 + Na]+: 339.1321; found: 339.1315.
(21) Synthesis of (R,S)-1′,3′-Dicyclohexyl-5-(2′′-hydroxyphenyl)-
spiro[(E)-2,3,6,7-tetrahydro-2H-1,4-oxazepine-7,4′-imidazo-
lidine]-2′,5′-dione (5a)
C25H33N3O4 (yellowish white solid, molecular weight 439.54
g/mol, 0.65 g, yield 59%, mp 96–97 °C). Compound 1a (1g, 2.5
mmol) was added to hydroxyethylene amine (or 2-aminoetha-
nol) (1 mL, 16.5 mmol) in CH2Cl2 (20 mL). The reaction mixture
was stirred at r.t. for 4 h. The volume of CH2Cl2 was then
reduced to ca. 5 mL to be purified in short plug column chroma-
tography using CH2Cl2 as eluent. The purified product 5a was
precipitated in hexane. 1H NMR (300.13 MHz, CDCl3): δ = 0.93–
2.30 (m, 20 H, CH2, cyclohexyl), 2.57–2.60 (m, 2 H, H-2), 3.11 (tt,
J = 12.0, 3.5 Hz, 1 H, H-1′′′a), 3.47 and 3.65 (AB, J = 17.8 Hz, 2 H,
H-6), 3.62–3.73 (m, 2 H, H-3), 3.97 (tt, J = 12.0, 3.5 Hz, 1 H, H-
1′′′b), 6.86–7.01 (m, 2 H, H-5′′, H-3′′), 7.45–7.53 (m, 1 H, H-4′′),
7.65 (dd, J = 8.1, 1.2 Hz, 1 H, H-6′′), 11.74 (s, 1 H, 2′′-OH) ppm.
13C NMR (75.47 MHz, CDCl3): δ = 25.07, 25.13, 25.81, 25.87,
26.1, 26.2, 29.2, 29.3, 30.2 and 30.5 (CH2, cyclohexyl), 42.4 (C-6),
42.7 (C-2), 51.5 (C-1′′′b), 52.1 (C-1′′′a), 61.5 (C-3), 75.5 (C-7/4′),
118.7 (C-1′′), 118.9 (C-5′′), 119.2 (C-3′′), 129.2 (C-6′′), 137.1 (C-
4′′), 155.1 (C-2′), 162.6 (C-2′′), 173.5 (C-5′), 200.5 (C-5) ppm.
HRMS (ESI+): m/z calcd for [C25H33N3O4 Na]+: 462.2369; found:
462.2342.
(22) Synthesis of (R,S)-1′,3′-Dicyclohexyl-4-(2′′-hydroxyphenyl)-
spiro[(E)-2,3-dihydro-1H-benzo[b][1,4]diazepine-2,4′-imid-
azolidine]-2′,5′-dione (6a) and (R,S)-1′,3′-Diisopropyl-4-(2′′-
hydroxyphenyl)-spiro[(E)-2,3-dihydro-1H-benzo[b][1,4]diaz-
epine-2,4′-imidazolidine]-2′,5′-dione (6b)
Compound 1a (1 g, 2.5 mmol) or 1b (0.8 g, 2.5 mmol), was
added to ortho-phenylenediamine (0.54 g, 5 mmol) in THF (40
mL) in the presence of a catalytic amount of DBU (few drops).
The reaction mixture was stirred at reflux overnight. After that,
the solution was reduced to ca. 5 mL to be purified in short plug
column chromatography using CH2Cl2 as eluent. The purified
product 6a or 6b, was recrystallized from a hexane–CH2Cl2 (5:1)
solution by slow evaporation at 6 °C.
Compound 6a: C29H34N4O3 (pale yellow crystal, molecular
weight 486.60 g/mol, 0.86 g, yield 71%, mp 147–149 °C). 1H
NMR (300.13 MHz, CDCl3): δ = 0.69–2.29 (m, 20 H, CH2, cyclo-
hexyl), 2.99 and 3.33 (AB, J = 14.0 Hz, 2 H, H-3), 3.06–3.19 and
3.82–3.97 (2 m, 2 H, H-1′′′a, H-1′′′b), 3.77 (s, 1 H, NH), 6.82–6.88
(m, 1 H, H-5′′), 6.89–6.93 (m, 1 H, H-7), 7.04 (d, J = 8.8 Hz, 1 H,
H-3′′), 7.14–7.19 (m, 2 H, H-8 and H-9), 7.28–7.41 (m, 3 H, H-4′′,
H-6′′, H-6), 14.71 (s, 1 H, 2′′-OH) ppm. 13C NMR (75.47 MHz,
CDCl3): δ = 22.6, 24.8, 25.7, 25.8, 25.9, 26.1, 29.2, 29.4, 30.8 and
31.5 (CH2, cyclohexyl), 33.5 (C-3), 51.3 and 51.7 (C-1′′′a and C-
1′′′b), 87.4 (C-2/4′), 118.1 (C-5′′), 118.5 (C-3′′), 119.1 (C-1′′),
121.5 (C-7), 123.6 (C-9), 127.6 (C-8), 128.1 (C-6), 128.5 (C-6′′),
133.4 (C-4′′), 135.3 (C-9a), 136.0 (C-5b), 152.7 (C-2′), 162.1 (C-
2′′), 167.0 (C-4), 170.5 (C-5′). HRMS (ESI+): m/z calcd for
[C29H34N4O3 + Na]+: 509.2529; found: 509.2527.Compound 6a:
C23H26N4O3 (bright yellow crystal, molecular weight = 406.47
g/mol, 0.64 g, yield 63%, mp 181–182 °C). 1H NMR (300.13 MHz,
CDCl3): δ = 1.33 and 1.47 (2 d, J = 6.7 Hz, 2 × 3 H, CH3, isopropyl),
1.41 and 1.44 (2 d, J = 7.2 Hz, 2 × 3 H, CH3, isopropyl), 3.00 and
3.32 (AB, J = 14.0 Hz, 2 H, H-3), 3.56–3.69 and 4.25–4.39 (2 m, 2
H, H-1′′′a, H-1′′′b), 3.83 (s, 1 H, NH), 6.80–6.88 (m, 1 H, H-5′′),
6.90–6.96 (m, 1 H, H-7), 7.04 (d, J = 8.2 Hz, 1 H, H-3′′), 7.10–7.21
(m, 2 H, H-8 and H-9), 7.24–7.42 (m, 3 H, H-4′′, H-6′′, H-6),
14.74 (s, 1 H, 2′′-OH) ppm. 13C NMR (75.47 MHz, CDCl3): δ =
19.6, 19.7, 22.0 and 21.6 (CH3, isopropyl), 33.5 (C-3), 43.7 and
45.6 (C-1′′′a and C-1′′′b), 87.1 (C-2/4′), 118.1 (C-5′′), 118.6 (C-
3′′), 119.2 (C-1′′), 121.6 (C-7), 123.6 (C-9), 127.7 (C-8), 128.3 (C-
6), 128.6 (C-6′′), 133.4 (C-4′′), 135.3 (C-9a), 135.8 (C-5b), 152.5
(C-2′), 162.2 (C-2′′), 166.7 (C-4), 170.6 (C-5′). HRMS (ESI+): m/z
calcd for [C23H26N4O3 + Na]+: 407.2083; found: 407.2100.
(23) Crystal Data for Compound 2a
2 × C24H32N4O3 + C3H6O, M = 907.15, monoclinic, space group
C2/c, Z = 4, a = 29.894(3) Å, b = 8.2853(8) Å, c = 22.364(2) Å,
β = 120.814(4)º, V = 4757.1(8) Å3, μ(Mo Kα) = 0.085 mm–1,
Dc = 1.267 g cm–3, colorless block, crystal size of 0.26 × 0.20 ×
0.18 mm3. Of a total of 68339 reflections collected, 6395 were
independent (Rint = 0.0615). Final R1 = 0.0438 [I > 2σ(I)] and
wR2 = 0.1201 (all data). Data completeness to θ = 25.24°, 99.7%.
CCDC 1024617.
(24) Crystal Data for Compound 4b
C19H26N4O3, M = 358.44, monoclinic, space group P21/c, Z = 4,
a = 10.3118(13) Å, b = 10.8672(14) Å, c = 17.551(2) Å,
β = 105.671(4)º, V = 1893.7(4) Å3, μ(Mo Kα) = 0.087 mm–1,
Dc = 1.257 g cm–3, yellow block, crystal size of 0.30 × 0.28 × 0.24
mm3. Of a total of 50806 reflections collected, 5091 were inde-
pendent (Rint = 0.0341). Final R1 = 0.0453 [I > 2σ(I)] and
wR2 = 0.1219 (all data). Data completeness to θ = 25.24°, 99.9%.
CCDC 1024618.
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(25) Crystal Data for Compound 6b
C23H26N4O3 + CH2Cl2, M = 491.40, monoclinic, space group P21/c,
Z = 4, a = 14.4092(9) Å, b = 9.1504(5) Å, c = 18.5751(11) Å,
β = 98.7540(19)º, V = 2420.6(2) Å3, μ(Mo Kα) = 0.302 mm–1,
Dc = 1.348 g cm–3, yellow prism, crystal size of 0.20 × 0.20 × 0.16
mm3. Of a total of 19864 reflections collected, 6504 were inde-
pendent (Rint = 0.0332). Final R1 = 0.0741 [I > 2σ(I)] and
wR2 = 0.1817 (all data). Data completeness to θ = 25.24°, 99.8%.
CCDC 1024619.
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